12 Biggest Mid-Day Losers For Thursday - Actinium Pharma (AMEX:ATNM)

Intra-Cellular Therapies Inc ITCI shares tumbled 63.2 percent to $15.60 after its lead product candidate, ITI-007, failed a late-stage study in schizophrenia. Apparently, the drug couldn't beat the placebo, nor could it equal the performance of the active control risperidone.
Alcobra Ltd ADHD shares dipped 55 percent to $2.08 after the company disclosed that the FDA has placed a full clinical hold on its IND applications for MDX in ADHD and Fragile X Syndrome. The company reported that it has received verbal notice of the clinical hold from the FDA.
Marinus Pharmaceuticals Inc MRNS dropped 28.2 percent to $1.96 after the company reported top-line results from a Phase 2 exploratory open-label clinical trial evaluating ganaxolone in females with PCDH19 pediatric epilepsy.
Shineco Inc TYHT shares fell 27.3 percent to $21.00. On Wednesday, Shineco priced IPO at $4.50 per share.
Actinium Pharmaceuticals Inc ATNM shares dropped 20.7 percent to $1.34. Actinium priced 8 million shares at $1.25 per share.
Real Goods Solar, Inc. RGSE fell 16.3 percent to $4.05. Real Goods Solar shares have dropped 78.96 percent over the past 52 weeks, while the S&P 500 index has gained 15.25 percent in the same period.
Galectin Therapeutics Inc GALT shares declined 14.2 percent to $1.20. H.C. Wainwright downgraded the rating on Galectin Therapeutics from Buy to Neutral, while lowering the price target from $8.00 to $1.50.
Stein Mart, Inc. SMRT shares dropped 11 percent to $6.71 after the company announced the resignation of Dawn Robertson as CEO. Sidoti & Co. downgraded Stein Mart from Buy to Neutral.
Fitbit Inc FIT shares declined 9.3 percent to $15.15. Pacific Crest downgraded Fitbit from Sector Weight to Underweight.
Sonus Networks, Inc. SONS fell 9 percent to $7.84. Cowen & Co. downgraded Sonus Networks from Market Perform to Underperform.
Kona Grill Inc KONA slipped 8.2 percent to $12.70. KeyBanc downgraded Kona Grill from Overweight to Sector Weight.
Genocea Biosciences Inc GNCA shares dropped 4.9 percent to $5.44. Genocea Biosciences disclosed that its Phase 2b trial of GEN-003 for genital herpes has achieved primary endpoint.

Market News and Data brought to you by Benzinga APIs